Changes in illicit drug use and markets with the COVID-19 pandemic and associated restrictions: findings from the Ecstasy and Related Drugs Reporting System, 2016-20.

"Declaration of interests A.P. has received untied educational grant from Seqirus and Mundipharma for study of opioid medications. R.B. has received untied educational grant from Mundipharma and Indivior for study of opioid medications. P.D. has received untied educational grant from Gilead sciences for work related to hepatitis C and an untied educational grant from Indivior. S.L. and P.D. have served as an unpaid member of an Advisory Board for Mundipharma. L.D. has received untied educational grant from Seqirus, Indivior and Mundipharma for study of opioid medications. All other authors have no conflicts of interest to declare."

"Drug Trends (including the EDRS) and the National Drug and Alcohol Research Centre are funded by the Department of Health, Australian Government under the Drug and Alcohol Program. S.L. was supported by funding from the Department of Health, Australian Government under the Drug and Alcohol Program through its core funding of The National Drug Research Institute at Curtin University. A.P. is supported by a National Health and Medical Research Council (NHMRC) Investigator Fellowship (no. 1174630). L.D. is supported by a NHMRC Senior Principal Research Fellowship (no. 1135991). L.D. is supported by National Institute of Health (NIH) National Institute on Drug Abuse (NIDA) grant (R01DA1104470)."